What New Research Says About GLP-1 Drugs and Cancer

• New research suggests GLP-1 drugs may be associated with lower rates of certain cancers and slower progression in some patients, but the evidence doesn’t prove they prevent or treat cancer.
• Researchers are studying whether these findings are connected to weight loss, improved insulin signaling, lower inflammation, immune effects, or other changes in cancer-related biology.
• For now, GLP-1 medications should be used for medically appropriate reasons like diabetes care or weight loss support, not as a cancer prevention strategy.

What Are GLP-1 Drugs?

GLP-1 drugs are medications that act on hormone pathways involved in appetite, fullness, blood sugar regulation, and digestion. GLP-1 stands for glucagon-like peptide-1, a hormone the body naturally makes after eating.

Medications in this category were first used in diabetes care because they help improve blood sugar control. Some GLP-1 medications are also used for chronic weight management. They can help reduce appetite, quiet cravings, slow stomach emptying, and help people feel full sooner.

You may recognize GLP-1-based medications by names like Ozempic, Wegovy, Mounjaro, and Zepbound. These medications are not all identical. Some primarily target the GLP-1 pathway, while others, like tirzepatide, also act on another hormone pathway called GIP. 

That difference matters because researchers are still learning how these medications may affect metabolism, inflammation, weight, and long-term health in ways that go beyond appetite alone.

Why Researchers Are Looking at GLP-1 Drugs and Cancer

Researchers are paying closer attention to GLP-1 drugs and cancer because obesity, metabolism, inflammation, insulin resistance, and cancer risk are deeply connected. Excess body fat is not just stored energy. It’s a biologically active tissue that can influence hormones, inflammatory signals, insulin levels, and the way cells grow and repair themselves.

The National Cancer Institute notes that obesity is linked to increased risk for several cancers, and that high insulin and insulin-like growth factor-1 levels are associated with increased risks of cancers, including colorectal, breast, ovarian, thyroid, prostate, and endometrial cancers.

This is where GLP-1 research becomes especially interesting. These medications can support weight loss and improve metabolic health, which may indirectly affect cancer risk. But newer research is asking whether GLP-1 drugs could also influence cancer biology in ways that are not explained by weight loss alone.

What The New Research Is Showing

Recent studies presented at the 2026 American Society of Clinical Oncology meeting looked at GLP-1 medications in relation to cancer prevention, cancer progression, and survival.

The findings are promising, especially in breast, colorectal, liver, lung, and pancreatic cancer research, but they are not definitive proof that GLP-1 drugs prevent or treat cancer. Many of the studies are observational, which means they can show an association but cannot prove cause and effect.

Breast Cancer

One of the most talked-about findings came from a Penn Medicine retrospective analysis of more than 110,000 women between the ages of 45 and 80. Researchers found that women who took GLP-1 medications were about 30% less likely to develop breast cancer than women who didn’t take GLP-1 medications.

This finding is especially interesting because breast cancer risk can be influenced by weight, hormones, insulin resistance, and inflammation. However, the study doesn’t prove that GLP-1 drugs directly prevent breast cancer. It shows a strong enough signal that researchers want to study the connection more carefully.

Cancer Progression

Another major area of interest is whether GLP-1 drugs may affect how cancer progresses after diagnosis.

An ASCO-reported real-world study looked at more than 12,000 people with stage I, II, or III lung, breast, colorectal, or liver cancer. Researchers found that people taking GLP-1 receptor agonists were less likely to progress to stage IV disease compared with similar patients taking DPP-4 inhibitors, another type of diabetes medication.

These findings suggest researchers should continue studying GLP-1 medications. They may influence inflammation, immune signaling, metabolism, or the environment around cancer cells.

Obesity-Associated Cancers

The cancer conversation around GLP-1 drugs didn’t start with the newest ASCO research. A 2024 study published in JAMA Network Open examined GLP-1s and 13 obesity-associated cancers in patients with type 2 diabetes. The study found that GLP-1 receptor agonists were associated with a lower risk of several obesity-associated cancers when compared with insulin.

That earlier research helped build the foundation for today’s bigger question. Are GLP-1 drugs lowering cancer risk mainly because they help people lose weight and improve metabolic health? Could they also have effects on cancer-related pathways independent of weight loss?

For now, the answer is still unknown. But the consistency across multiple cancer types is one reason this research is getting more attention.

Pancreatic Cancer and Chronic Pancreatitis

A 2026 ASCO Gastrointestinal Cancers Symposium abstract reported that GLP-1 receptor agonist use was associated with a significantly reduced incidence of pancreatic cancer in patients with chronic pancreatitis, including those with chronic pancreatitis and type 2 diabetes. 

This is an important finding, but it should be interpreted carefully. Pancreatic cancer is complex, and GLP-1 medications also have a history of safety questions related to pancreatitis. Anyone with pancreatic disease, chronic pancreatitis, or a history of pancreatic cancer should discuss GLP-1 medication use with a qualified medical provider before starting or continuing treatment.

Why This Doesn’t Mean GLP-1s Prevent Cancer

The research around GLP-1 drugs and cancer is exciting, but it’s important not to jump ahead of the evidence. Most of the studies so far are observational, which means they can show a connection between GLP-1 use and cancer outcomes, but they cannot prove that the medication caused the difference.

People who take GLP-1 medications may also differ from people who don’t in ways that are hard to fully measure. They may have different access to healthcare, screening habits, diabetes care, weight loss patterns, or overall health behaviors. Researchers try to account for these factors, but observational data always has limits.

That’s why randomized clinical trials matter. Until those studies are done, GLP-1 medications shouldn’t be described as cancer prevention drugs or cancer treatments. The current findings are promising enough to study seriously, but not strong enough to change cancer prevention or oncology care recommendations.

Could GLP-1 Drugs Affect Cancer Beyond Weight Loss?

One of the biggest questions in this research is whether the possible cancer benefit comes mainly from weight loss? Or, whether GLP-1 medications may affect cancer-related biology in other ways.

Weight loss itself can improve metabolic health, lower insulin resistance, reduce inflammation, and decrease excess body fat. All of which may influence cancer risk. But researchers are also studying whether GLP-1 drugs may have broader effects on the body’s internal environment.

Possible areas of interest include:

• Inflammation: Chronic inflammation can create conditions that support abnormal cell growth and cancer progression.
• Insulin signaling: High insulin and insulin-like growth factor activity may influence the growth of certain cancers.
• Immune function: Researchers are exploring whether GLP-1 medications may affect immune signaling in ways that change how the body responds to cancer.
• Metabolic pathways: GLP-1 drugs may influence how cells use energy, store fat, and respond to metabolic stress.
• Tumor environment: Early research is asking whether these medications could affect the environment around cancer cells, including inflammation and immune activity.

What About the Thyroid Cancer Warning?

A common question about GLP-1 medications is whether they increase thyroid cancer risk. Some GLP-1 and GLP-1/GIP medications carry a boxed warning related to thyroid C-cell tumors seen in animal studies. Because of this, they are generally not recommended for people with a personal or family history of medullary thyroid carcinoma. This also pertains to people with Multiple Endocrine Neoplasia syndrome type 2.

That warning is separate from the newer research exploring whether GLP-1 medications may be associated with lower rates of certain cancers or slower progression in some patients. The thyroid warning is part of individual safety screening, while the newer cancer research is still early. It’s also not strong enough to change cancer prevention or oncology treatment guidelines.

Exciting Research, Careful Next Steps

The newest research on GLP-1 drugs and cancer is promising, but it is still early. These studies raise important questions about how weight, inflammation, insulin signaling, metabolism, and cancer risk may be connected. However, they don’t prove that GLP-1 medications prevent or treat cancer.

For now, GLP-1 medications should be used for their approved and medically appropriate purposes. This includes diabetes care and chronic weight management when appropriate.

Our approach to medical weight loss is provider-guided. It”s personalized, and grounded in your health history, goals, and how your body responds over time. If you are curious whether a GLP-1 medication is right for weight loss support, we can help. We review safety considerations and build a plan designed for sustainable progress.

Schedule a GLP-1 weight loss consultation at Kintsu MedSpa & Wellness to take the next step with clear guidance and medical support.